14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.

Szczegóły
Abstrakt

Tytuł:: 14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.
Autorzy:: Pair FS; Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Yacoubian TA; Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: .
Źródło:: Trends in pharmacological sciences [Trends Pharmacol Sci] 2021 Apr; Vol. 42 (4), pp. 226-238. Date of Electronic Publication: 2021 Jan 28.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Review
Język:: English
Imprint Name(s):: Publication: Barking : Published By Elsevier In Association With The International Union Of Pharmacology
Original Publication: Amsterdam, Published by Elsevier in association with the International Union of Pharmacology.
MeSH Terms:: 14-3-3 Proteins*
Neurodegenerative Diseases*/drug therapy
Humans ; Models, Molecular ; Signal Transduction
References:: Acta Neuropathol. 2004 Oct;108(4):279-86. (PMID: 15235803)
Dement Geriatr Cogn Disord. 2008;25(4):317-20. (PMID: 18319590)
J Am Chem Soc. 2020 Jul 8;142(27):11772-11783. (PMID: 32501683)
Nature. 1995 Jul 13;376(6536):191-4. (PMID: 7603574)
Ann Neurol. 2003 Jul;54(1):135. (PMID: 12838532)
Alzheimers Dement. 2020 Mar 10;:. (PMID: 32157811)
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E34-43. (PMID: 24351927)
Biochemistry. 1999 Sep 21;38(38):12499-504. (PMID: 10493820)
Trends Biochem Sci. 2014 Nov;39(11):556-69. (PMID: 25440716)
Neurobiol Dis. 2011 Jul;43(1):201-12. (PMID: 21440628)
Angew Chem Int Ed Engl. 2012 Oct 15;51(42):10472-98. (PMID: 22952048)
ACS Chem Biol. 2020 Apr 17;15(4):1026-1035. (PMID: 32142251)
Mol Psychiatry. 2012 Apr;17(4):451-66. (PMID: 22124272)
Eur J Neurol. 2008 Mar;15(3):219-22. (PMID: 18290843)
Anticancer Agents Med Chem. 2012 Sep;12(7):791-800. (PMID: 22263802)
Hum Mol Genet. 2014 Nov 1;23(21):5615-29. (PMID: 24895406)
Cell. 2020 Apr 2;181(1):151-167. (PMID: 32243788)
J Neurochem. 2010 Jun;113(6):1577-88. (PMID: 20374424)
ACS Chem Biol. 2020 Feb 21;15(2):305-310. (PMID: 31971771)
Int J Mol Sci. 2019 Jul 18;20(14):. (PMID: 31323761)
J Neurochem. 2010 Mar;112(6):1353-67. (PMID: 19943854)
Prog Mol Biol Transl Sci. 2019;166:19-61. (PMID: 31521232)
Chem Biol. 2013 Apr 18;20(4):583-93. (PMID: 23601647)
Blood. 1999 Mar 15;93(6):1809-16. (PMID: 10068651)
Neurosci Lett. 2004 Mar 4;357(2):143-6. (PMID: 15036595)
Neuron. 2017 Mar 8;93(5):1082-1093.e5. (PMID: 28279353)
Proteins. 2006 Apr 1;63(1):35-42. (PMID: 16444738)
Biol Psychiatry. 2015 Sep 15;78(6):386-95. (PMID: 25863357)
FEBS Lett. 1994 Sep 26;352(2):163-6. (PMID: 7925968)
Nat Commun. 2018 Sep 17;9(1):3785. (PMID: 30224724)
J Mol Biol. 2009 Mar 6;386(4):913-9. (PMID: 19244612)
FASEB J. 2015 Oct;29(10):4133-44. (PMID: 26103986)
Angew Chem Int Ed Engl. 2018 Oct 8;57(41):13470-13474. (PMID: 30025189)
Drug Discov Today Technol. 2013 Dec;10(4):e541-7. (PMID: 24451646)
IUBMB Life. 2014 Jan;66(1):52-62. (PMID: 24408864)
Chem Sci. 2019 Jan 25;10(10):2869-2874. (PMID: 30996864)
Nat Neurosci. 2006 Oct;9(10):1231-3. (PMID: 16980962)
J Neurosci. 2014 Sep 3;34(36):12168-81. (PMID: 25186760)
EMBO J. 2008 Sep 3;27(17):2305-16. (PMID: 19172738)
Nature. 1997 Aug 28;388(6645):839-40. (PMID: 9278044)
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6133-7. (PMID: 20832303)
Sci Rep. 2015 Jul 24;5:12434. (PMID: 26207352)
Proteomics. 2004 Jun;4(6):1551-61. (PMID: 15174125)
Cell Death Dis. 2010;1:e2. (PMID: 21152247)
Dev Neurobiol. 2016 Jun;76(6):600-14. (PMID: 26297819)
Biochemistry. 2017 Aug 1;56(30):3972-3982. (PMID: 28681606)
ChemMedChem. 2016 Apr 19;11(8):911-8. (PMID: 26644359)
ACS Chem Neurosci. 2018 Nov 21;9(11):2639-2654. (PMID: 29722962)
Chem Biol. 2012 Jan 27;19(1):42-50. (PMID: 22284353)
J Mol Biol. 1999 Oct 22;293(2):321-31. (PMID: 10550212)
Elife. 2016 Sep 13;5:. (PMID: 27623012)
Nat Rev Neurol. 2013 Aug;9(8):445-54. (PMID: 23857047)
Leukemia. 2013 Jan;27(1):118-29. (PMID: 22858987)
J Biol Chem. 2004 Aug 27;279(35):37061-8. (PMID: 15220353)
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8873-E8881. (PMID: 30158171)
Biochem J. 2010 Sep 15;430(3):405-13. (PMID: 20659021)
Biochem Soc Trans. 2002 Aug;30(4):387-91. (PMID: 12196100)
J Biol Chem. 2000 Aug 18;275(33):25247-54. (PMID: 10840038)
Lancet. 2011 Mar 19;377(9770):1019-31. (PMID: 21371747)
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76. (PMID: 18344392)
Eur J Biochem. 1992 Jun 1;206(2):453-61. (PMID: 1317796)
J Neuropathol Exp Neurol. 2002 Mar;61(3):245-53. (PMID: 11895039)
PLoS One. 2010 Oct 19;5(10):e13367. (PMID: 20976054)
Ann Clin Transl Neurol. 2017 Jun 07;4(7):466-477. (PMID: 28695147)
Front Mol Neurosci. 2017 Dec 14;10:417. (PMID: 29311810)
J Neurochem. 2009 Jan;108(1):33-43. (PMID: 19014373)
J Am Chem Soc. 2018 Oct 31;140(43):14498-14510. (PMID: 30296824)
Biochem Biophys Res Commun. 1997 Sep 29;238(3):758-63. (PMID: 9325163)
Biochem J. 2010 Sep 15;430(3):393-404. (PMID: 20642453)
Acta Neuropathol Commun. 2021 Jan 7;9(1):13. (PMID: 33413679)
J Biol Chem. 2006 Jan 6;281(1):626-37. (PMID: 16253990)
ACS Omega. 2020 Sep 24;5(39):25029-25035. (PMID: 33043180)
J Chem Inf Model. 2020 Dec 28;60(12):6555-6565. (PMID: 33138374)
Neurology. 2005 Dec 27;65(12):1863-72. (PMID: 16237129)
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6867-71. (PMID: 21962576)
J Biol Chem. 2005 Dec 23;280(51):42364-74. (PMID: 16223726)
Drug Discov Today. 2011 Apr;16(7-8):284-7. (PMID: 21315179)
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7084-8. (PMID: 2902623)
Bioorg Med Chem Lett. 2018 Feb 15;28(4):646-650. (PMID: 29398541)
J Neurosci. 2018 Sep 19;38(38):8211-8232. (PMID: 30093536)
PLoS One. 2011;6(7):e21720. (PMID: 21799745)
J Med Chem. 2018 May 10;61(9):3755-3778. (PMID: 28968506)
Hum Mol Genet. 2007 Jan 15;16(2):223-32. (PMID: 17200152)
Oncogene. 2018 Oct;37(42):5587-5604. (PMID: 29915393)
J Am Chem Soc. 2019 Feb 27;141(8):3524-3531. (PMID: 30707565)
Angew Chem Int Ed Engl. 2015 Dec 21;54(52):15720-4. (PMID: 26537010)
Cell Chem Biol. 2020 Jun 18;27(6):657-667.e6. (PMID: 32220335)
Cell. 1997 Dec 26;91(7):961-71. (PMID: 9428519)
Angew Chem Int Ed Engl. 2010 Jun 1;49(24):4129-32. (PMID: 20437433)
J Enzyme Inhib Med Chem. 2019 Dec;34(1):657-664. (PMID: 30727786)
Nat Rev Drug Discov. 2016 Apr;15(4):275-92. (PMID: 26794270)
J Neurochem. 1968 Apr;15(4):265-72. (PMID: 4966699)
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2489-93. (PMID: 24504455)
Neurobiol Dis. 2006 Aug;23(2):329-41. (PMID: 16750377)
Angew Chem Int Ed Engl. 1998 Nov 2;37(20):2754-2794. (PMID: 29711117)
Bioinformatics. 2015 Jul 15;31(14):2276-83. (PMID: 25735772)
Planta. 1975 Jan;126(1):61-73. (PMID: 24430088)
Sci Transl Med. 2018 Jul 25;10(451):. (PMID: 30045977)
J Biol Chem. 1995 Mar 17;270(11):5706-9. (PMID: 7890696)
PLoS One. 2011 Mar 01;6(3):e17153. (PMID: 21390248)
Database (Oxford). 2014 Feb 05;2014:bat085. (PMID: 24501395)
J Neurochem. 1994 Dec;63(6):2259-65. (PMID: 7964746)
Hum Mol Genet. 2016 Jan 1;25(1):109-22. (PMID: 26546614)
Hum Mol Genet. 2008 Oct 15;17(20):3212-22. (PMID: 18658164)
Neuroscience. 2015 Oct 29;307:73-82. (PMID: 26314634)
Blood. 1994 Apr 15;83(8):2038-44. (PMID: 8161775)
Chemistry. 2012 May 21;18(21):6520-7. (PMID: 22467351)
J Biol Chem. 2001 Nov 30;276(48):45193-200. (PMID: 11577088)
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16212-6. (PMID: 21908710)
EMBO J. 2007 Feb 7;26(3):902-13. (PMID: 17235285)
Biochemistry. 2013 Sep 17;52(37):6445-55. (PMID: 23962087)
J Neurosci. 2014 Apr 2;34(14):4801-8. (PMID: 24695700)
Grant Information:: P50 NS108675 United States NS NINDS NIH HHS; R01 NS112203 United States NS NINDS NIH HHS; R01 NS088533 United States NS NINDS NIH HHS; R56 NS115767 United States NS NINDS NIH HHS; T32 GM008361 United States GM NIGMS NIH HHS
Contributed Indexing:: Keywords: 14-3-3; Alzheimer’s disease; Parkinson’s disease; protein–protein interactions
Substance Nomenclature:: 0 (14-3-3 Proteins)
Entry Date(s):: Date Created: 20210201 Date Completed: 20210831 Latest Revision: 20231111
Update Code:: 20240104
PubMed Central ID:: PMC8011313
DOI:: 10.1016/j.tips.2021.01.001
PMID:: 33518287
: Czasopismo naukowe

14-3-3 proteins are a family of proteins expressed throughout the body and implicated in many diseases, from cancer to neurodegenerative disorders. While these proteins do not have direct enzymatic activity, they form a hub for many signaling pathways via protein-protein interactions (PPIs). 14-3-3 interactions have proven difficult to target with traditional pharmacological methods due to the unique nature of their binding. However, recent advances in compound development utilizing a range of tools, from thermodynamic binding site analysis to computational molecular modeling techniques, have opened the door to targeting these interactions. Compounds are already being developed targeting 14-3-3 interactions with potential therapeutic implication for neurodegenerative disorders, but challenges still remain in optimizing specificity and target engagement to avoid unintended negative consequences arising from targeting 14-3-3 signaling networks.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)

Informacja